论文部分内容阅读
目的探讨多奈哌齐治疗脑卒中后失语的疗效和安全性。方法脑卒中后失语患者62例,随机分为多奈哌齐治疗组(31例)及对照组(31例)。治疗组给予多奈哌齐5mg,1次/d,共8周;对照组用安慰剂(维生素C)1片,1次/d,采用西方成套测验(WAB)和交流能力问卷(CAL)评定患者语言功能和日常生活交流能力。结果治疗后,治疗组WAB、CAL评分明显高于治疗前,与对照组相比,WAB中的口语表达、听理解、复述、命名,均有统计学意义(t值分别为2.70,4.32,2.57,4.53,均P<0.01),CAL分值差异亦有统计学意义(t=2.89,P<0.01)。治疗组无明显不良反应。结论多奈哌齐治疗卒中后失语安全有效。
Objective To investigate the efficacy and safety of donepezil in the treatment of post-stroke aphasia. Methods Sixty-two patients with post-stroke aphasia were randomly divided into donepezil-treated group (n = 31) and control group (n = 31). The treatment group was given donepezil 5mg once a day for 8 weeks. The control group was given 1 placebo (vitamin C) once a day, and the Western Language Proficiency Test (WAB) and Exchange Ability Questionnaire (CAL) Ability to communicate with everyday life. Results After treatment, the scores of WAB and CAL in the treatment group were significantly higher than those before treatment. Compared with the control group, the oral expression, auditory understanding, repetition and naming in WAB were statistically significant (t = 2.70, 4.32, 2.57 , 4.53, all P <0.01). There was also a statistically significant difference in CAL scores (t = 2.89, P <0.01). Treatment group no obvious adverse reactions. Conclusion Donepezil is safe and effective in treating aphasia after stroke.